Correlates of antiretroviral utilization among hospitalized HIV-infected crack cocaine users

AIDS Research and Human Retroviruses

Volumn 28, Issue 9, 2012, Pages 807-814

  Doshi, Rupali Kotwal ^a   Vogenthaler, Nicholas S ^a   Lewis, Sarah ^b   Rodriguez, Allan ^c   Metsch, Lisa ^c   Rio, Carlos Del ^a,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARRY UNIVERSITY   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COCAINE DEPENDENCE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DRUG UTILIZATION; FEMALE; HETEROSEXUALITY; HOMELESSNESS; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTPATIENT CARE; POPULATION RESEARCH; PRIORITY JOURNAL; VIRUS LOAD;

EID: 84865463265     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0329     Document Type: Article

References (54)

1. Zwahlen M, Harris R, May M, et al.: Mortality of HIVinfected patients starting potent antiretroviral therapy: Comparison with the general population in nine industrialized countries. Int J Epidemiol 2009;38 (6):1624-1633.
2. Wood E, Hogg RS, Lima VD, et al.: Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 2008;300 (5):550-554.
3. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, and Moore RD: Self-reported antiretroviral therapy in injection drug users. JAMA 1998;280 (6):544-546.
4. Strathdee SA, Palepu A, Cornelisse PG, et al.: Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998;280 (6):547-549. (Pubitemid 28377675)
5. Cunningham WE, Sohler NL, Tobias C, et al.: Health services utilization for people with HIV infection: Comparison of a population targeted for outreach with the U.S. population in care. Med Care 2006;44 (11):1038-1047. (Pubitemid 44674036)
6. Montaner JS, Wood E, Kerr T, et al.: Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes. J Acquir Immune Defic Syndr 2010;55 (Suppl 1):S5-S9.
7. Robison LS, Westfall AO, Mugavero MJ, et al.: Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses 2008;24 (11):1347-1355.
8. Sohler NL, Wong MD, Cunningham WE, Cabral H, Drainoni ML, and Cunningham CO: Type and pattern of illicit drug use and access to health care services for HIV-infected people. AIDS Patient Care and STDs 2007;21 (Suppl 1):S68-S76.
9. Metsch LR, Bell C, Pereyra M, et al.: Hospitalized HIVinfected patients in the era of highly active antiretroviral therapy. Am J Public Health 2009;99 (6):1045-1049.
10. Ellerbrock TV, Lieb S, Harrington PE, et al.: Heterosexually transmitted human immunodeficiency virus infection among pregnant women in a rural Florida community. N Engl J Med 1992;327 (24):1704-1709.
11. Edlin BR, Irwin KL, Faruque S, et al.: Intersecting epidemics-crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. N Engl J Med 1994;331 (21):1422-1427.
12. Bell C, Metsch LR, Vogenthaler N, et al.: Never in care: Characteristics of HIV-infected crack cocaine users in 2 US cities who have never been to outpatient HIV care. J Acquir Immune Defic Syndr 2010;54 (4):376-380.
13. Sharpe TT, Lee LM, Nakashima AK, Elam-Evans LD, and Fleming PL: Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Community Health 2004;29 (2):117-127. (Pubitemid 39012830)
14. Sullivan PS, Campsmith ML, Nakamura GV, Begley EB, Schulden J, and Nakashima AK: Patient and regimen characteristics associated with self-reported nonadherence to antiretroviral therapy. PLoS One 2007;2 (6):e552.
15. Cook JA, Burke-Miller JK, Cohen MH, et al.: Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS 2008;22 (11):1355-1363.
16. Siddiqui NS, Brown LS Jr, and Makuch RW: Short-term declines in CD4 levels associated with cocaine use in HIV-1 seropositive, minority injecting drug users. J Natl Med Assoc 1993;85 (4):293-296.
17. Nacher M, Adenis A, Hanf M, et al.: Crack cocaine use increases the incidence of AIDS-defining events in French Guiana. AIDS 2009;23 (16):2223-2226.
18. Baum MK, Rafie C, Lai S, Sales S, Page B, and Campa A: Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr 2009;50 (1):93-99.
19. Moore J, Schuman P, Schoenbaum E, Boland B, Solomon L, and Smith D: Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America. AIDS 1999;13 (17):2459-2468.
20. Arnsten JH, Demas PA, Grant RW, et al.: Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002;17 (5):377-381. (Pubitemid 34626108)
21. Ingersoll K: The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care 2004;16 (2):199-211. (Pubitemid 38183583)
22. Kyser M, Buchacz K, Bush TJ, et al.: Factors associated with non-adherence to antiretroviral therapy in the SUN study. AIDS Care 2011;23 (5):601-611.
23. Tapp C, Milloy MJ, Kerr T, et al.: Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis 2011;11:86.
24. Palepu A, Milloy MJ, Kerr T, Zhang R, and Wood E: Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. J Urban Health 2011;88 (3):545-555.
25. Tucker JS, Burnam MA, Sherbourne CD, Kung FY, and Gifford AL: Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med 2003;114 (7):573-580. (Pubitemid 36577260)
26. Knowlton AR, Arnsten JH, Eldred LJ, et al.: Antiretroviral use among active injection-drug users: The role of patientprovider engagement and structural factors. AIDS Patient Care STDS 2010;24 (7):421-428.
27. Hightow-Weidman LB, Jones K, Phillips G 2nd, Wohl A, and Giordano TP: Baseline clinical characteristics, antiretroviral therapy use, and viral load suppression among HIV-positive young men of color who have sex with men. AIDS Patient Care STDS 2011;25 (Suppl 1):S9-S14.
28. DHHS: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011 1-161 Available at www.aidsinfo.nih.gov/ ContentFiles/Adultand AdolescentGL.pdf. Accessed March 5, 2011.
29. Valverde EE, Purcell DW, Waldrop-Valverde D, et al.: Correlates of depression among HIV-positive women and men who inject drugs. J Acquir Immune Defic Syndr 2007;46 (Suppl 2): S96-S100. (Pubitemid 350293786)
30. Vogenthaler NS, Hadley C, Rodriguez AE, Valverde EE, Del Rio C, and Metsch LR: Depressive symptoms and food insufficiency among HIV-infected crack users in Atlanta and Miami. AIDS Behav 2011;15 (7):1520-16.23.
31. Sherbourne CD and Stewart AL: The MOS social support survey. Soc Sci Med 1991;32 (6):705-714.
32. Bakken S, Holzemer WL, Brown MA, et al.: Relationships between perception of engagement with health care provider and demographic characteristics, health status, and adherence to therapeutic regimen in persons with HIV/ AIDS. AIDS Patient Care STDS 2000;14 (4):189-197. (Pubitemid 30225313)
33. Hosmer D and Lemeshow S: Applied Logistic Regression. John Wiley & Sons, New York, 1989.
34. Korthuis PT, Tozzi MJ, Nandi V, et al.: Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr 2011;56 (Suppl 1):S39-S45.
35. Weiss L, Netherland J, Egan JE, et al.: Integration of buprenorphine/ naloxone treatment into HIV clinical care: Lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr 2011;56 (Suppl 1):S68-S75.
36. Samet JH, Friedmann P, and Saitz R: Benefits of linking primary medical care and substance abuse services: Patient, provider, and societal perspectives. Arch Intern Med 2001;161 (1):85-91. (Pubitemid 32052147)
37. Selwyn PA, Budner NS, Wasserman WC, and Arno PS: Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Rep 1993;108 (4):492-500. (Pubitemid 23239335)
38. Shorter D and Kosten TR: Novel pharmacotherapeutic treatments for cocaine addiction. BMC Med 2011;9:119.
39. ADA: HIV Care Program: AIDS Drug Assistance Program. http://health.state. ga.us/programs/stdhiv/adap.asp. Accessed March 18, 2011.
40. Buchanan D, Kee R, Sadowski LS, and Garcia D: The health impact of supportive housing for HIV-positive homeless patients: A randomized controlled trial. Am J Public Health. 2009 99 (Suppl 3 S675-S680.
41. Wolitski RJ, Kidder DP, Pals SL, et al.: Randomized trial of the effects of housing assistance on the health and risk behaviors of homeless and unstably housed people living with HIV. AIDS Behav 2010;14 (3):493-503.
42. Saha S, Jacobs EA, Moore RD, and Beach MC: Trust in physicians and racial disparities in HIV care. AIDS Patient Care STDS 2010;24 (7):415-420.
43. Alford DP, Bridden C, Jackson AH, et al.: Promoting substance use education among generalist physicians: An evaluation of the Chief Resident Immersion Training (CRIT) program. J Gen Intern Med 2009;24 (1):40-47.
44. Grenard JL, Munjas BA, Adams JL, et al.: Depression and medication adherence in the treatment of chronic diseases in the United States: A meta-analysis. J Gen Intern Med 2011;26 (10):1175-1182.
45. Akincigil A, Wilson IB, Walkup JT, Siegel MJ, Huang C, and Crystal S: Antidepressant treatment and adherence to antiretroviral medications among privately insured persons with HIV/AIDS. AIDS Behav 2011;15 (8):1819-1828.
46. Olatunji BO, Mimiaga MJ, O'Cleirigh C, and Safren SA: Review of treatment studies of depression in HIV. Top HIV Med 2006;14 (3):112-124.
47. Daughters SB, Magidson JF, Schuster RM, and Safren SA: ACT HEALTHY: A combined cognitive-behavioral depression and medication adherence treatment for HIVinfected substance users. Cogn Behav Pract 2010;17 (3): 309-321.
48. Campsmith ML, Nakashima AK, and Jones JL: Association between crack cocaine use and high-risk sexual behaviors after HIV diagnosis. J Acquir Immune Defic Syndr 2000;25 (2):192-198.
49. Hudgins R, McCusker J, and Stoddard A: Cocaine use and risky injection and sexual behaviors. Drug Alcohol Depend 1995;37 (1):7-14.
50. Timpson SC, Williams ML, Bowen AM, and Keel KB: Condom use behaviors in HIV-infected African American crack cocaine users. Subst Abuse 2003;24 (4):211-220. (Pubitemid 37408931)
51. Metsch LR, McCoy HV, McCoy CB, Miles CC, Edlin BR, and Pereyra M: Use of health care services by women who use crack cocaine. Women Health 1999;30 (1):35-51.
52. Melchior LA, Huba GJ, Gallagher T, et al.: Unmet needs in groups of traditionally underserved individuals with HIV/ AIDS: Empirical models. Home Health Care Serv Q 2001; 19 (1-2):29-51.
53. Brouwer ES, Napravnik S, Smiley SG, Corbett AH, and Eron JJ Jr: Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV care. Pharmacoepidemiol Drug Safety 2011;20 (4):432-439.
54. Kerr T, Hogg RS, Yip B, Tyndall MW, Montaner J, and Wood E: Validity of self-reported adherence among injection drug users. J Int Assoc Physicians AIDS Care (Chic) 2008;7 (4):157-159.